These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 38711133)
21. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters. Hsieh M-S; Hsu C-W; Liao H-C; Lin C-L; Chiang C-Y; Chen M-Y; Liu S-J; Liao C-L; Chen H-W J Virol; 2024 Feb; 98(2):e0154623. PubMed ID: 38299865 [TBL] [Abstract][Full Text] [Related]
23. The preparation of N-IgY targeting SARS-CoV-2 and its immunomodulation to IFN-γ production in vitro. Lyu J; Bao L; Shen X; Yan C; Zhang C; Wei W; Yang Y; Li J; Dong J; Xiao L; Zhou X; Li Y Int Immunopharmacol; 2021 Jul; 96():107797. PubMed ID: 34162159 [TBL] [Abstract][Full Text] [Related]
24. Novel neutralizing chicken IgY antibodies targeting 17 potent conserved peptides identified by SARS-CoV-2 proteome microarray, and future prospects. Li J; Liang T; Hei A; Wang X; Li H; Yu X; Zhao R; Gao P; Fang C; Zhou J; Li M; He E; Skog S Front Immunol; 2022; 13():1074077. PubMed ID: 36618358 [TBL] [Abstract][Full Text] [Related]
25. Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters. Trimpert J; Herwig S; Stein J; Vladimirova D; Adler JM; Abdelgawad A; Firsching TC; Thoma T; Sehouli J; Osterrieder K; Gruber AD; Sawitzki B; Sander LE; Cichon G Viruses; 2021 Nov; 13(11):. PubMed ID: 34835096 [TBL] [Abstract][Full Text] [Related]
26. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199 [TBL] [Abstract][Full Text] [Related]
27. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Wang Y; Yang C; Song Y; Coleman JR; Stawowczyk M; Tafrova J; Tasker S; Boltz D; Baker R; Garcia L; Seale O; Kushnir A; Wimmer E; Mueller S Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34193524 [TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2-specific immunoglobulin Y antibodies are protective in infected mice. El-Kafrawy SA; Odle A; Abbas AT; Hassan AM; Abdel-Dayem UA; Qureshi AK; Wong LR; Zheng J; Meyerholz DK; Perlman S; Zumla A; Azhar EI PLoS Pathog; 2022 Sep; 18(9):e1010782. PubMed ID: 36121829 [TBL] [Abstract][Full Text] [Related]
29. Leptospira-specific immunoglobulin Y (IgY) is protective in infected hamsters. Lv T; Xie X; Diao L; Jiang S; Ding Y; Yuan X; Gong L; Chen X; Zhang W; Cao Y Vaccine; 2024 May; 42(13):3220-3229. PubMed ID: 38641497 [TBL] [Abstract][Full Text] [Related]
30. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera. Espeseth AS; Yuan M; Citron M; Reiserova L; Morrow G; Wilson A; Horton M; Rukhman M; Kinek K; Hou F; Li SL; Li F; Choi Y; Heidecker G; Luo B; Wu G; Zhang L; Strable E; DeStefano J; Secore S; Mukhopadhyay TK; Richardson DD; Sayeed E; Welch LS; Bett AJ; Feinberg MB; Gupta SB; Cooper CL; Parks CL EBioMedicine; 2022 Aug; 82():104203. PubMed ID: 35915046 [TBL] [Abstract][Full Text] [Related]
32. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants. Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Immunogenic Response of a Novel Enterobactin Conjugate Vaccine in Chickens for the Production of Enterobactin-Specific Egg Yolk Antibodies. Zeng X; Wang H; Huang C; Logue CM; Barbieri NL; Nolan LK; Lin J Front Immunol; 2021; 12():629480. PubMed ID: 33868248 [TBL] [Abstract][Full Text] [Related]
34. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation. Jeong H; Choi YM; Seo H; Kim BJ Front Immunol; 2021; 12():637654. PubMed ID: 33732258 [TBL] [Abstract][Full Text] [Related]
35. A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters. Frantz PN; Barinov A; Ruffié C; Combredet C; Najburg V; de Melo GD; Larrous F; Kergoat L; Teeravechyan S; Jongkaewwattana A; Billon-Denis E; Tournier JN; Prot M; Levillayer L; Conquet L; Montagutelli X; Tichit M; Hardy D; Fernandes P; Strick-Marchand H; Di Santo J; Simon-Lorière E; Bourhy H; Tangy F Nat Commun; 2021 Nov; 12(1):6277. PubMed ID: 34725327 [TBL] [Abstract][Full Text] [Related]
36. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related]
37. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L Front Immunol; 2021; 12():697074. PubMed ID: 34262569 [TBL] [Abstract][Full Text] [Related]
38. Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity. Faizuloev E; Gracheva A; Korchevaya E; Smirnova D; Samoilikov R; Pankratov A; Trunova G; Khokhlova V; Ammour Y; Petrusha O; Poromov A; Leneva I; Svitich O; Zverev V Vaccine; 2023 Jan; 41(4):892-902. PubMed ID: 36528447 [TBL] [Abstract][Full Text] [Related]
39. General applicability of chicken egg yolk antibodies: the performance of IgY immunoglobulins raised against the hypoxia-inducible factor 1alpha. Camenisch G; Tini M; Chilov D; Kvietikova I; Srinivas V; Caro J; Spielmann P; Wenger RH; Gassmann M FASEB J; 1999 Jan; 13(1):81-8. PubMed ID: 9872932 [TBL] [Abstract][Full Text] [Related]
40. The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate. Jung BK; An YH; Jang JJ; Jeon JH; Jang SH; Jang H PLoS One; 2022; 17(2):e0263684. PubMed ID: 35134091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]